Advanced Oncotherapy (AVO) – Additional financing agreement

Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that on Tuesday 25 April it drew down a further £2 million as part of the 12-month convertible and redeemable loan agreement announced on 27 March 2017 with Blackfinch Investment Ltd, through its subsidiary Henslow Trading Limited. This […]

Advanced Oncotherapy (AVO) – Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed yesterday that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, yesterday purchased 30,000 ordinary shares of 25 pence each in the Company at an average price […]

Advanced Oncotherapy (AVO) – Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed on Friday 8 July 2016 that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, on Friday 8 July 2016 purchased 10,000 ordinary shares of 25 pence […]

Advanced Oncotherapy (AVO) – Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed yesterday that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, yesterday purchased 10,000 ordinary shares of 25 pence each in the Company at 112.0 pence per […]

Advanced Oncotherapy (AVO) – Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed yesterday that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, yesterday purchased 50,000 ordinary shares of 25 pence each in the Company at 102.5 pence per […]

Advanced Oncotherapy (AVO) secures of £24m financing for Harley Street

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has signed an agreement with a fund advised by Metric Capital Partners LLP, a pan-European private capital fund manager, whereby Metric Capital will invest £24 million in a financing facility to support the Company’s provision of vendor financing for the […]

Advanced Oncotherapy – Additional Director Dealing

Advanced Oncotherapy (AVO) announces that Michael Sinclair, Executive Chairman of the Company, on 18 December 2015 purchased 500,000 ordinary shares of 1 penny each in the Company at 6.25 pence per Ordinary Share. The Company also announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, […]

Advanced Oncotherapy – Additional Director Dealing

Advanced Oncotherapy (AVO) announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, yesterday purchased 1,000,000 ordinary shares of 1 penny each in the Company at 5.75 pence per Ordinary Share. Following this transaction, Michael Bradfield now holds 123,768,510 Ordinary Shares representing 8.73% of the issued […]

Advanced Oncotherapy – Director Dealing

Advanced Oncotherapy (AVO) announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, yesterday purchased 750,000 ordinary shares of 1 penny each in the Company at 5.5 pence per Ordinary Share. Following this transaction, Michael Bradfield now holds 122,768,510 Ordinary Shares representing 8.66% of the […]